There is described a versatile and environment-friendly one-pot process for the preparation of nanoparticles of noble metals in hydrogel, obtainable at room temperature using quaternized hydroxyethylcellulose.

The subject matter described herein is directed to stable L-cysteine compositions for injection, comprising: L-cysteine or a pharmaceutically acceptable salt thereof and/or hydrate thereof in an amount from about 10 mg/mL to about 100 mg/mL; Aluminum in an amount from about 1.0 parts per billion (ppb) to about 250 ppb; cystine in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; pyruvic acid in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; a pharmaceutically acceptable carrier, comprising water; headspace O.sub.2 that is less than 1.0%; dissolved oxygen present in the carrier in an amount from about 0.01 parts per million (ppm) to about 1 ppm, wherein the composition is enclosed in a single-use container having a volume of from 10 mL to 100 mL. Also described are compositions for a total parenteral nutrition regimen and methods for their use.

The subject matter described herein is directed to stable L-cysteine compositions for injection, comprising: L-cysteine or a pharmaceutically acceptable salt thereof and/or hydrate thereof in an amount from about 10 mg/mL to about 100 mg/mL; Aluminum in an amount from about 1.0 parts per billion (ppb) to about 250 ppb; cystine in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; pyruvic acid in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; a pharmaceutically acceptable carrier, comprising water; headspace O.sub.2 that is less than 1.0%; dissolved oxygen present in the carrier in an amount from about 0.01 parts per million (ppm) to about 1 ppm, wherein the composition is enclosed in a single-use container having a volume of from 10 mL to 100 mL. Also described are compositions for a total parenteral nutrition regimen and methods for their use.

The subject matter described herein is directed to stable L-cysteine compositions for injection, comprising: L-cysteine or a pharmaceutically acceptable salt thereof and/or hydrate thereof in an amount from about 10 mg/mL to about 100 mg/mL; Aluminum in an amount from about 1.0 parts per billion (ppb) to about 250 ppb; cystine in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; pyruvic acid in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; a pharmaceutically acceptable carrier, comprising water; headspace O.sub.2 that is less than 1.0%; dissolved oxygen present in the carrier in an amount from about 0.01 parts per million (ppm) to about 1 ppm, wherein the composition is enclosed in a single-use container having a volume of from 10 mL to 100 mL. Also described are compositions for a total parenteral nutrition regimen and methods for their use.

The subject matter described herein is directed to stable L-cysteine compositions for injection, comprising: L-cysteine or a pharmaceutically acceptable salt thereof and/or hydrate thereof in an amount from about 10 mg/mL to about 100 mg/mL; Aluminum in an amount from about 1.0 parts per billion (ppb) to about 250 ppb; cystine in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; pyruvic acid in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; a pharmaceutically acceptable carrier, comprising water; headspace O.sub.2 that is less than 1.0%; dissolved oxygen present in the carrier in an amount from about 0.01 parts per million (ppm) to about 1 ppm, wherein the composition is enclosed in a single-use container having a volume of from 10 mL to 100 mL. Also described are compositions for a total parenteral nutrition regimen and methods for their use.

The present invention concerns the field of therapy of muscle, joint and/or skeletal diseases. In particular, the invention relates to a composition comprising a first solution comprising preparations of Aconitum napellus, Arnica montana, radix, Bellis perennis, Belladonna, Calendula officinalis, Chamomilla, Echinacea, Echinacea purpurea, Hamamelis virginiana, Hepar sulfuris calcareum, Hypericum perforatum, Mercuris solubilis, Millefolium, and Symphytum officinale, and a second solution comprising preparations of Arnica montana, radix, Dulcamara, Rhus toxicodendron, Sanguinaria Canadensis, and Sulphur. Further provided is a method of treating and/or preventing the progression of a disease comprising administering to a subject in need of a treatment a therapeutically effective amount of the said composition or said first and said second solution. The invention also contemplates a kit comprising said first and said second solution.

The present invention concerns the field of therapy of muscle, joint and/or skeletal diseases. In particular, the invention relates to a composition comprising a first solution comprising preparations of Aconitum napellus, Arnica montana, radix, Bellis perennis, Belladonna, Calendula officinalis, Chamomilla, Echinacea, Echinacea purpurea, Hamamelis virginiana, Hepar sulfuris calcareum, Hypericum perforatum, Mercuris solubilis, Millefolium, and Symphytum officinale, and a second solution comprising preparations of Arnica montana, radix, Dulcamara, Rhus toxicodendron, Sanguinaria Canadensis, and Sulphur. Further provided is a method of treating and/or preventing the progression of a disease comprising administering to a subject in need of a treatment a therapeutically effective amount of the said composition or said first and said second solution. The invention also contemplates a kit comprising said first and said second solution.

The present invention concerns the field of therapy of muscle, joint and/or skeletal diseases. In particular, the invention relates to a composition comprising a first solution comprising preparations of Aconitum napellus, Arnica montana, radix, Bellis perennis, Belladonna, Calendula officinalis, Chamomilla, Echinacea, Echinacea purpurea, Hamamelis virginiana, Hepar sulfuris calcareum, Hypericum perforatum, Mercuris solubilis, Millefolium, and Symphytum officinale, and a second solution comprising preparations of Arnica montana, radix, Dulcamara, Rhus toxicodendron, Sanguinaria Canadensis, and Sulphur. Further provided is a method of treating and/or preventing the progression of a disease comprising administering to a subject in need of a treatment a therapeutically effective amount of the said composition or said first and said second solution. The invention also contemplates a kit comprising said first and said second solution.

The present invention comprises compositions that provide anti-glycation activity comprising a mineral extract composition or a mogroside/mineral extract composition or a mogroside composition. Such compositions are useful for methods of preventing, treating and inhibiting the effects of glycation in the body. The methods of the present invention comprise use of anti-glycation composition for the treatment and prevention of glycation related conditions including diabetes, atherosclerosis, arthritis, mental conditions and vision impairment.

The present invention comprises compositions that provide anti-glycation activity comprising a mineral extract composition or a mogroside/mineral extract composition or a mogroside composition. Such compositions are useful for methods of preventing, treating and inhibiting the effects of glycation in the body. The methods of the present invention comprise use of anti-glycation composition for the treatment and prevention of glycation related conditions including diabetes, atherosclerosis, arthritis, mental conditions and vision impairment.